▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1086 by analyst upside · 2026-09-29
IONS
Ionis Pharmaceuticals, Inc.
Healthcare · Market Cap $8B · P/E 0x
ANALYST PRICE TARGET
+83.5%
implied upside to consensus target
Current Price $45.57
Consensus Target $83.64
Bull Target $105.0
Bear Target $54.0
Analysts Covering 22
ANALYST CONSENSUS - BUY
Strong Buy
9
Buy
9
Hold
5
Sell
0
52-Week Low $43.01
52-Week High $86.74
YTD Return -42.8%
FUNDAMENTALS
Market Cap $8B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.48
PEG Ratio 27.33
Dividend Yield N/A
Revenue (TTM) $874M
Profit Margin -64.7%
52-WEEK RANGE
52-Week Low $43.01
52-Week High $86.74
Current Price $45.57
Bear Target $54.0
Bull Target $105.0
● Now $45.57 ● Target $83.64
TRADING DATA
Avg Volume 3.7M
YTD Return -42.8%
Analyst Count 22
Consensus Buy
Upside to Target +83.5%
Last Updated 2026-09-29

ANALYST SUMMARY

Ionis Pharmaceuticals, Inc. (IONS) is currently trading at $45.57 with a Wall Street consensus price target of $83.64, implying potential upside of 83.5% over the next 12 months. 22 analysts currently cover IONS, with a consensus rating of Buy - 78% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $105.0, while the most cautious has a target of $54.0.

IONS operates in the Healthcare sector with a market capitalisation of $8B. The stock is down 42.8% year-to-date and is currently trading near the lower end of its 52-week range of $43.01 – $86.74.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IONS, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-09-24 31% win rate (48 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-09-22 43% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-09-15 62% win rate (8 calls)
Barclays - Reiterated
Overweight → Overweight 2026-09-09 Building track record
Morgan Stanley - Reiterated
Overweight → Overweight 2026-09-08 Building track record
Goldman Sachs - Reiterated
Neutral → Neutral 2026-09-08 Building track record
BMO Capital - Reiterated
Market Perform → Market Perform 2026-09-08 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-09-08 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
46
out of 100
Coverage depth
24/30
Consensus clarity
8/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →